StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) company profile

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

About BioLineRx

Pharmaceutical Preparations, SIC 2834

BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases. Its first approved drug is APHEXDA (motixafortide), a peptide indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma patients. Commercialization and development of APHEXDA are handled by partners, including Ayrmid Pharma globally outside Asia and Auspex Bioscience in Asia. In addition, the company develops motixafortide for pancreatic cancer and other solid tumors, and collaborates on the clinical development of GLIX1, an oral small molecule candidate targeting DNA damage response in glioblastoma and other malignancies.

The company's primary executive offices are located in Modi'in, Israel. Commercial distribution rights for its approved product span Asia, the United States, and additional global markets through international licensing partnerships, while development activities and corporate collaborations extend across Israel, Europe, and Asia.

Summary of the business section of BioLineRx's latest annual report, written by StockData.

Company profile

Company

Legal name
BioLineRx Ltd.
Headquarters
Modi-In, Israel
Address
2 Hamaayan Street, Modi-In Technology Park ISRAEL
Phone
972-8-642-9100
Employees
20, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman, Tel Aviv, Israel

Stock & identifiers

Ticker
BLRX
Exchange
Nasdaq
IPO date
Jul 27, 2011
Shares outstanding
2.61B, Mar 8, 2026
Filer category
Non-accelerated filer
Stock splits
1-for-40 reverse, Jan 30, 2025; 1-for-15 reverse, Jul 15, 2019
SEC CIK
1498403
CUSIP
09071M304
ISIN
US09071M3043
FIGI
BBG001Y26LK0
Share class FIGI
BBG001Y26MC7
LEI
529900AKIOSC15Y63R18
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Philip A. SerlinChief Executive Officer5,131,800
Mali ZeeviChief Financial Officer1,311,000
Shaoyu YanDirector–
Sandra PanemDirector–
Rami DarDirector–
Avraham MolchoDirector–
Raphael HofsteinDirector–
Gal Avraham CohenDirector–
Aharon SchwartzDirector3,705,000
Barbara-Jean Anne Bormann-KennedyDirector–

Employees

Headcount reported in annual reports

“As of March 8, 2026, we had 20 full-time employees and 4 part-time”

See a number that looks wrong?